Ono drops depression and anxiety trials as ONO-1110 misses in all five Phase 2 studies
- Ono's endocannabinoid modulator ONO-1110 failed its primary endpoints across five Phase 2 studies.
- The company is ending the depression and social anxiety programs, citing no efficacy signals.
- Studies in postherpetic neuralgia, fibromyalgia and Hunner-type interstitial cystitis will continue, with more trials planned given improved pain scores.
💡 Points Based on public reports
Five Phase 2 misses is a verdict on the mechanism in psychiatry, not a dosing problem. Ono's decision to keep pain indications after missed primary endpoints leans on secondary pain-score gains, a thin basis. Expect ONO-1110 to shrink into a niche pain bet while the neuroscience pipeline's weight shifts to other assets.
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure ↗